Lexaria Bioscience (LEXX) Stock Forecast & Price Target

Lexaria Bioscience Corp's DehydraTECH technology significantly enhances the bio-absorption of active pharmaceutical ingredients, particularly cannabinoids and nicotine, achieving improvements of up to 27 times compared to conventional formulations and reducing onset time to mere minutes. The company’s revenue streams are diversified across four segments, with Intellectual Property Licensing contributing the largest share, and it operates geographically in the U.S. and Canada. Furthermore, projections indicate a rise in estimated shares outstanding, reaching 33 million by the end of FY2026, which reflects the company's growth and potential market expansion.

Lexaria Bioscience Corp reported a significant net loss of $3.8 million for fiscal 3Q25, translating to a loss of $0.21 per share, indicating ongoing financial challenges. The company's research into its DehydraTECH technology shows only a marginal reduction in HbA1c levels, suggesting limited efficacy in its medical applications, particularly concerning gastrointestinal adverse events associated with GLP-1 drugs. With revenue primarily generated from intellectual property licensing and ongoing losses, the financial outlook remains concerning, impacting investor confidence.